Ovarian cancer: adding HIPEC to surgery is cost-effective

  • Koole SN & al.
  • J Clin Oncol
  • 28 Jun 2019

  • curated by Deepa Koli
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Adding hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery (CRS) results in a substantial gain in quality-adjusted life years (QALYs) in patients with stage III ovarian cancer.
  • The resulting incremental cost-effectiveness ratio (ICER) was within the current willingness-to-pay threshold in the Netherlands (€80,000/QALY).

Why this matters

  • Findings support for reimbursing treatment costs in patients undergoing interval CRS with HIPEC in other countries with comparable health care systems.

Study design

  • Cost-efficacy analysis of data from the OVHIPEC trial.
  • 245 patients with stage III ovarian cancer were randomly assigned to receive interval CRS with or without HIPEC.
  • Funding: None disclosed.

Key results

  • Total health care costs were €70,046 in patients undergoing interval CRS vs €85,791 in those receiving interval CRS+HIPEC.
  • The mean QALYs in the interval CRS group were 2.12 and 2.68 in the interval CRS+HIPEC group.
  • The resulting ICER €28,299/QALY for HIPEC+CRS was within the willingness-to-pay threshold.
  • The utility for recurrence-free survival, the number of hospitalization days, and the utility for recurrent disease with grade 3-4 toxicity affected the calculated ICER most.

Limitations

  • Costs of surgery, diagnostic tests, the administered regimens, and toxicities and recurrences were based on assumptions.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit